TQB 2825
Alternative Names: TQB-2825Latest Information Update: 02 Jun 2025
At a glance
- Originator Chia Tai Tianqing Pharmaceutical Group
- Class Antineoplastics; Bispecific antibodies; Immunotherapies
- Mechanism of Action Cytotoxic T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Diffuse large B cell lymphoma
- Phase I Haematological malignancies
Most Recent Events
- 23 Apr 2025 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Combination therapy, First-line therapy) in China (Parenteral) (NCT06829771)
- 23 Apr 2025 Phase-I/II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06829771)
- 12 Mar 2025 Phase-II clinical trials in Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (Parenteral) (NCT06854445)